Coherus Awaits August 2022 Date As FDA Accepts Ranibizumab Biosimilar

Company Set For Showdown With Samsung Bioepis For Biosimilar Lucentis

 
• By Dean Rudge
FDASignBldg21Entrance_1200x675
Samsung Bioepis' Byooviz became the first FDA-approved Lucentis biosimilar last month • Source: Shutterstock

More from Biosimilars

More from Products